U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257068) titled 'Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study' on Nov. 18.
Brief Summary: To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
Study Start Date: April 14, 2026
Study Type: INTERVENTIONAL
Condition:
Checkpoint Inhibitor
Pilot Study
Diabetes Melletus
Intervention:
OTHER: Infliximab
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....